|
Feb 19, 02:33
|
Evercore Notes AbbVie Inc.’s (ABBV) Tremfya Gains Market Share, But Future Earnings Growth May Be Limited
|
N/A |
—
|
—
|
No analysis
|
|
Feb 18, 22:38
|
Incyte Remains Undervalued As Opzelura And Niktimvo Scale
|
N/A |
—
|
—
|
No analysis
|
|
Feb 18, 21:15
|
Harbor Dividend Growth Leaders ETF Q4 Contributors & Detractors
|
N/A |
—
|
—
|
No analysis
|
|
Feb 18, 17:35
|
What's going on in today's session: S&P500 movers
|
N/A |
—
|
—
|
No analysis
|
|
Feb 18, 10:00
|
IXJ: Healthcare Sector Dashboard For February
|
N/A |
—
|
—
|
No analysis
|
|
Feb 18, 08:24
|
Piper Sandler Maintains Overweight on AbbVie, Raises Price Target to $299
|
N/A |
—
|
—
|
No analysis
|
|
Feb 17, 21:10
|
Assessing AbbVie (ABBV) Valuation After Strong Results And New Rinvoq Vitiligo Filings
|
N/A |
—
|
—
|
No analysis
|
|
Feb 17, 15:32
|
Facial Injectable Analysis Report 2025: An $18.89 Billion Market by 2029, Driven by New Product Launches, Emerging Markets, AI Innovations, Male Aesthetics, Younger Demographics
|
N/A |
—
|
—
|
No analysis
|
|
Feb 17, 13:35
|
10 Health Care Stocks With Whale Alerts In Today's Session
|
N/A |
—
|
—
|
No analysis
|
|
Feb 17, 01:11
|
AbbVie: Dominating Immunology While Building Oncology Upside
|
N/A |
—
|
—
|
No analysis
|
|
Feb 16, 12:05
|
AbbVie Conference: Year-End HS Readouts, SubQ SKYRIZI Data and New IBD Combo Roadmap in Focus
|
N/A |
—
|
—
|
No analysis
|
|
Feb 15, 22:25
|
1 No-Brainer Dividend Stock to Buy on the Dip
|
N/A |
—
|
—
|
No analysis
|
|
Feb 15, 10:07
|
3 Dividend Stocks to Hold for the Next 20 Years
|
N/A |
—
|
✓
|
# ABBV News Report — 2026-02-15
## Overview
| Metric | Value |
|--------|-------|
| **Ticker** | ABBV |
| **Date** | 2026-02-15 |
| **Total Articles...
|
|
Feb 14, 23:11
|
AbbVie’s Botox Lawsuit Puts Medicare Pricing Risks In Focus
|
N/A |
—
|
—
|
No analysis
|
|
Feb 14, 13:35
|
2 Unstoppable Dividend Stocks to Buy If There's a Stock Market Sell-Off
|
N/A |
—
|
✓
|
# ABBV News Report — 2026-02-14
## Overview
| Metric | Value |
|--------|-------|
| **Ticker** | ABBV |
| **Date** | 2026-02-14 |
| **Total Articles...
|
|
Feb 14, 07:30
|
Kraft Heinz: Looks Like Berkshire Got Its Wish (Rating Downgrade)
|
N/A |
—
|
—
|
No analysis
|
|
Feb 13, 23:01
|
Abbott Laboratories: A Key Reduction in Robert Bruce's Portfolio
|
N/A |
—
|
—
|
No analysis
|
|
Feb 13, 14:57
|
Where is AbbVie Inc. (ABBV) Headed According to the Street?
|
N/A |
—
|
—
|
No analysis
|
|
Feb 13, 13:00
|
Merck stock upside: Why Deutsche Bank sees 26% growth despite Keytruda patent
|
N/A |
—
|
—
|
No analysis
|
|
Feb 13, 12:57
|
AbbVie Inc. (ABBV) Presents at Piper Sandler Virtual Novel Targets in Immunology Symposium Transcript
|
N/A |
—
|
—
|
No analysis
|
|
Feb 13, 00:22
|
West Pharmaceutical Services (WST) Is Up 5.2% After Strong 2025 Results And 2026 Organic Growth Outlook
|
N/A |
—
|
—
|
No analysis
|
|
Feb 12, 17:37
|
This Is Graco’s Dividend Score After Paying Investors
|
N/A |
—
|
✓
|
# ABBV News Report — 2026-02-12
## Overview
| Metric | Value |
|--------|-------|
| **Ticker** | ABBV |
| **Date** | 2026-02-12 |
| **Total Articles...
|
|
Feb 12, 16:32
|
AbbVie Inc. stock outperforms competitors on strong trading day
|
N/A |
—
|
—
|
No analysis
|
|
Feb 12, 15:35
|
IRWD Rises 307% in 6 Months: Is This an Indication to Buy the Stock?
|
N/A |
—
|
—
|
No analysis
|
|
Feb 12, 12:14
|
Is It Too Late To Consider AbbVie (ABBV) After Its Strong Multi Year Run?
|
N/A |
—
|
—
|
No analysis
|
|
Feb 12, 10:04
|
1 Reason I'm Never Selling AbbVie Stock
|
N/A |
—
|
—
|
No analysis
|
|
Feb 12, 09:42
|
AbbVie Inc. (ABBV) Achieves Record Net Sales on Diversified Growth Platform
|
N/A |
—
|
—
|
No analysis
|
|
Feb 12, 00:49
|
Evercore ISI Cuts AbbVie Inc. (ABBV) PT, Says Consensus for 2026 and 2027 Still Looks Beatable
|
N/A |
—
|
—
|
No analysis
|
|
Feb 11, 23:49
|
AbbVie sues US health agency over Botox price controls
|
N/A |
—
|
—
|
No analysis
|
|
Feb 11, 23:39
|
Avalo Therapeutics Eyes Q2 2026 Phase IIb LOTUS Readout for AVTX-009 in Hidradenitis Suppurativa
|
N/A |
—
|
—
|
No analysis
|
|
Feb 11, 18:10
|
AbbVie Sues HHS Over Selection Of Botox For IRA Medicare Drug Negotiations
|
N/A |
—
|
—
|
No analysis
|
|
Feb 11, 16:06
|
2 Urgent Sells And 2 No Brainer Dividend Buys
|
N/A |
—
|
—
|
No analysis
|
|
Feb 11, 10:00
|
P/E Ratio Insights for AbbVie
|
N/A |
—
|
—
|
No analysis
|
|
Feb 11, 05:35
|
The 5 Most Interesting Analyst Questions From AbbVie’s Q4 Earnings Call
|
N/A |
—
|
—
|
No analysis
|